Mark Foletta, Interim CFO at Biocept, holds 0.00 shares in Biocept (Ticker: BIOCQ), holds 15.04K shares in Forte Biosciences (Ticker: FBRX), holds ― shares in Enanta Pharmaceuticals (Ticker: ENTA). Most recently, Mark Foletta ― shares of Biocept on ― for an estimated value of ―.
Mark Foletta latest transaction was an Uninformative Buy of ―.
What was Mark Foletta's most profitable transaction?
Mark Foletta’s most profitable transaction was an Informative Sell of DXCM stock on September 9, 2016. The return on the trade was 23.30%.
What is Mark Foletta's role in Biocept?
Mark Foletta's role in Biocept is Interim CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.